Details of the Brain Tumor Satellite Symposium can be found within the pages of this newsletter. Members of the Tumor Section receive a registration discount to attend the symposium.
Another educational activity sponsored by the Tumor Section at the AANS Annual Meeting in Chicago includes an immunotherapy workshop organized by Roberta Glick, MD, which will take place Sunday, April 7, 12-6 p.m. at the Sheraton Hotel and Towers (Sheraton Ballroom I). In addition, Jeffery Bruce, MD, has once again organized a highly informative course on the subject of principles of neuro-oncology for the general neurosurgical practitioner (details inside). This Practical Clinic will be held on Sunday, April 7, 2002. Several executive members of the Tumor Section will be participating in this course.
Joseph Piepmeier, MD, editor of the Journal of Neuro-Oncology, has described an outstanding benefit for members of the Tumor Section by offering a significant discount toward a subscription to the journal. Details of this offer can be found within the pages of this newsletter. This is yet another tangible example of how the Tumor Section continues to work for its membership, and we thank Dr. Piepmeier for facilitating this special offer.
We look forward to seeing all of you at the AANS Annual Meeting in Chicago April 6-11, 2002. Tumor Section Highlights at the 2002 AANS Annual Meeting 029 Update on Tumors for the General Neurosurgeon Sunday, April 7, 2002, 8:00 AM-12 PM Director: Jeffrey N. Bruce Faculty: Ossama Al-Mefty, Michael W. McDermott, Mitchel S. Berger, Thomas C. Origitano, Joseph M. Piepmeier, Corey Raffel, James T. Rutka, Raymond Sawaya, Jack P. Rock Clinic Fee: $450 Material Fee: $0 Total: $450 This clinic will provide the practicing clinician with an up-todate overview of current management strategies for all types of benign and malignant brain tumors. The seminar includes current research topics but emphasizes practical management issues. Learning Objectives: After completing this clinic participants should be able to identify the state-of-the-art management of benign and malignant brain tumors (including glial tumors, meningiomas, acoustic neuromas, skull base tumors, pediatric tumors, metastases, craniopharyngiomas, and pineal region tumors), and discuss current concepts in glioma management (including surgical techniques, adjuvant treatments, tumor biology, and practical clinical management decisions), and apply current knowledge about brain tumors to daily clinical practice decision-making.
Kluwer Academic Publishers
is pleased to announce that you can now receive a full annual subscription at a special discount to the
Journal of Neuro-Oncology
The 2002 subscription rate to the members of the AANS/CNS Section on Tumors is $258.00. This represents a greater than 60% reduction in the regular price.
The annual subscription includes 12 monthly issues plus 3 additional special issues focused on topics of interest to our readers. 
UPDATE FOR 2002:
This outstanding scientific tumor program has been organized to include numerous invited speakers with expertise in brain tumor research and therapy. Specific research topics, which will be formally presented and reviewed, include novel delivery strategies for anti-tumor agents, skull base treatment paradigms, and translational strategies for adult brain tumors. A special lecture on neural stem cells will be given by Arturo AlvarezBuylla, MD. For any questions concerning this program, please contact Nalin Gupta, the 2002 Scientific Program chairman, at nalin@itsa.ucsf.edu, or contact the AANS at (847) 378-0500.
Continuing Medical Education Credit
This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the American Association of Neurological Surgeons and the AANS/ CNS Section on Tumors. The Accreditation Council for Continuing Medical Education (ACCME) accredits AANS to sponsor continuing medical education for physicians. The AANS designated this educational activity for a maximum of 10 hours in AANS/CNS Section on Tumors Fifth Biennial Brain Tumor Satellite Symposium category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours that he or she actually spent in the educational activity.
Hotel Information
Rooms for the Brain Tumor Satellite Symposium are still available at the Sheraton Chicago Hotel and Towers. Call (800) 
Web Page
The Awards Committee would like to thank Frederick Lang, MD, for bringing the Web pages on awards and grants up to date (www.neurosurgery.org/tumor/awards.html) Descriptions of each award within the AANS/CNS Section on Tumors can be found as well as deadlines, instructions for submission, award amounts and past winners. Thanks also to James T. Rutka, MD, and Raymond Sawaya, MD, for their review of all materials during the update process.
Awards Process
At each semi-annual meeting of the AANS and CNS, the Mahaley, Preuss, and Young Investigator awards are presented. These awards are determined by the abstract with the highest average score (weighted average of 10 reviewers) as judged through a peer review process. The completed manuscript is submitted to the section chair. A single individual can only win each award once.
The NBTF Translational Research Grant is reviewed separately by a scientific advisory panel from the NBTF. The panel notifies the chair of the Tumor Section who the recipient will be.
For the Farber Award, a subcommittee composed of Dr. Rutka, T he American College of Surgeons Oncology Group (ACOSOG) has activated study Z0300, "a phase III randomized trial of the role of whole brain radiation therapy in addition to radiosurgery in the management of patients with one to three cerebral metastases." Z0300 is the first study opened by the group's Brain and Central Nervous System Organ Site Committee.
Participating patients will receive either radiosurgery (RS) alone (Arm 1) or RS combined with whole brain radiation therapy (WBRT) (Arm 2). The primary objective of the study is to ascertain if one treatment, compared to the other, is associated with better overall survival. Secondary objectives will compare time to local failure, quality of life, duration of functional independence, long-term neurocognitive status, and post-treatment toxicity.
The study provides an opportunity to gain critical comparative data about therapeutic options for patients with cerebral metastases arising from an extra-cerebral primary tumor. The ACOSOG has set an accrual goal of 96 patients per year for five years, with a total accrual of 480 patients.
Anthony Asher, MD, the director of the Brain Tumor Program at Carolinas Medical Center in Charlotte, N.C., is the study chair for ACOSOG Z0300. Dr. Asher also serves as the Brain and CNS Organ Site Committee Chair for the ACOSOG.
ACOSOG Opens Z0300, Group's First Neurosurgery Study
The trial will be open to all ACOSOG members. Interested surgeons and oncologists need to become ACOSOG members before participating in the study. Membership applications and other information about participating in ACOSOG trials can be found on the group's Web site at www.acosog.org. There is no application fee. Questions about the membership process can be directed to Angela Venetta, ACOSOG membership coordinator, at (919) 668-8549 or via e-mail to venet001@surgerytrials.duke.edu.
Physicians participating in the Z0300 trial will also need to attend a study-specific education course (SSEC) prior to enrolling patients in the trial. The first SSEC for Z0300 was held Saturday, March 2, at the ACOSOG Coordinating Center at Duke University. The SSEC will also be offered on Friday, April 5 at the Sheraton Chicago Hotel and Towers, one day before the American Association of Neurological Surgeons Annual Meeting.
The ACOSOG is funded by the National Cancer Institute to conduct prospective, randomized, clinical trials evaluating surgical therapies in the management of patients with malignant tumors.
For more information about Z0300 or other ACOSOG trials, please contact Meggan Monroe, ACOSOG public relations coordinator, at (919) 668-8156 or via e-mail to monro015@surgerytrials.duke.edu. chairman of the AANS/CNS Section on Tumors, Edward Shaw, MD, president of the Society for Neuro-Oncology, Mitchell Berger, MD, from the Tumor Section's advisory board, and Mr. Jim Farber takes into consideration names submitted by the executive committee.
Award Updates
Members should be aware of two changes related to the Mahaley Award and Farber Award.
The Mahaley Award dollar amount will be increased to $1000 from $500 as of the CNS 2002 meeting. The section would like to thank Janice Brewer and the board of the National Brain Tumor Foundation for this increase.
The Farber Award, sponsored by the Farber Foundation and Mr. Jim Farber, will now be awarded on alternate years at the AANS and Society for Neuro-Oncology annual meetings. The awardee will be a promising new investigator who is achieving significant results early in his or her career. The schedule for presentation of the award and recipient lecture will be:
AANS 2002 Finally the awards committee would like to thank our sponsors for their continued support:
American Brain Tumor Foundation
The Young Investigator Award National Brain Tumor Foundation
The Mahaley Award The Translational Research Grant
The Preuss Foundation
The Preuss Award The Farber Foundation and Mr. Jim Farber
The Farber Award
